1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [ef177090-841a-434c-8688-347a8f599821] => Array ( [runtime-id] => ef177090-841a-434c-8688-347a8f599821 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [2c561ba6-6721-48b6-a415-c6b37eb91a4f] => Array ( [runtime-id] => 2c561ba6-6721-48b6-a415-c6b37eb91a4f [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;476d751859bfec6c29f4fd06b1a5f8a63aad85a0 ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [ef177090-841a-434c-8688-347a8f599821] => Array ( [runtime-id] => ef177090-841a-434c-8688-347a8f599821 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [2c561ba6-6721-48b6-a415-c6b37eb91a4f] => Array ( [runtime-id] => 2c561ba6-6721-48b6-a415-c6b37eb91a4f [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;476d751859bfec6c29f4fd06b1a5f8a63aad85a0 ) ) )Table 3:Demographic, clinical, and imaging data according to clinical outcome
Favorable Outcome (n = 12) Unfavorable Outcome (n = 15) P Value Age (year) 46.4 ± 13.9 58.7 ± 15.2 .034 Sex (M/F) 8/4 5/10 n.s. NIHSS score 15 ± 4 21 ± 5 <.01 Serum glucose level (mg/dL) 135.6 ± 38.1 136.7 ± 29.7 n.s. Core (mL) 8.6 ± 7.8 19.8 ± 14.5 .03 TTP/CBV mismatch ratio (%) 75.4 ± 19.8 55.8 ± 23 .03 Infarct volume (mL) 11.3 ± 11.2 36.8 ± 15.7 <.01 Infarct growth (%) 31.2 ± 28 90 ± 45 <.01 Time to IAT (min) 61.2 ± 36.5 66.6 ± 35.9 n.s. Time to recanalization (min) 338 ± 50 371 ± 36 n.s Recanalization rate (TIMI, 2–3) 11/12 8/15 .03 Symptomatic hemorrhage 1 1 Thrombolytic agent n.s UK 6/17 11/17 rtPA 6/10 4/10 ASPECTS 9 8.6 n.s.
Note:—n.s. indicates not significant; UK, urokinase; IAT, intra-arterial thrombolysis; rtPA, recombinant tissue plasminogen activator; ASPECTS, Alberta Stroke Program Early CT Score.